Low doses of controlled-release paroxetine in the treatment of late-life depression: A randomized, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 70, Issue 1, 2009, Pages 46-57

  Rapaport, Mark Hyman ^a,e   Lydiard, R Bruce ^b   Pitts, Cornelius D ^c   Schaefer, Desiree ^c   Bartolic, Edward I ^d   Iyengar, Malini ^c   Carfagno, Michelle ^c   Lipschitz, Alan ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Southeast Health Consultants LLC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d i3 Research   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HERBACEOUS AGENT; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AGED; ANKLE FRACTURE; AORTA ANEURYSM; ARTICLE; BACKACHE; BIRTH DEFECT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFUSION; CONGENITAL MALFORMATION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISABILITY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FEMUR FRACTURE; HAMILTON SCALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFLUENZA; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; OSTEOARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; THORAX PAIN; TREATMENT DURATION; URINARY TRACT INFECTION; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PATIENT SATISFACTION; PERSONALITY INVENTORY; QUALITY OF LIFE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 60349099679     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.06m02996     Document Type: Article

References (41)

1. Huang BY, Cornoni-Huntley J, Hays JC, et al. Impact of depressive symptoms on hospitalization risk in community-dwelling older persons. J Am Geriatr Soc 2000;48:1279-1284
2. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(suppl 20):9-15
3. Wittchen HU, Holsboer F, Jacobi F. Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. J Clin Psychiatry 2001;62(suppl 26):23-28
4. Katona C. Managing depression and anxiety in the elderly patient. Eur Neuropsychopharmacol 2000 Dec;10(suppl 4):S427-S432
5. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001;18:355-368
6. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005;45:1106-1122
7. Mamdani MM, Parikh SV, Austin PC, et al. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000;157:360-367
8. Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-153
9. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000;157:729-736
10. Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60(suppl 20):16-20
11. Katona CLE, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13:100-108
12. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985 Mar;46:20-25
13. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. Psychopharmacol Bull 2003;37(suppl 1):29-41
14. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(2, suppl):21-26
15. Dunner DL. An overview of paroxetine in the elderly. Gerontology 1994;40(suppl 1):21-27
16. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002 Jul;63(7):577-584
17. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003 Sep;64(9):1065-1074
18. Trivedi MH, Pigott TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Oct;65(10):1356-1364
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
21. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
23. Williams JBW. The Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scales (SIGH-AD). New York, NY: New York State Psychiatric Institute; 1988
24. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
26. Sheikh RL, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontologist 1986;5:165-173
27. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
28. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-803
29. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003;64(suppl 13):18-25
30. Roose SP, Sackeim HA, Krishnan KR, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004;161:2050-2059
31. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006;14:361-370
32. Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004 Feb;65(2):222-229
33. Sheehan DV, Burnham DB, Iyengar MK, et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005 Jan;66(1):34-40
34. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-2304
35. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10:541-550
36. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84
37. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000 Mar;61(3):196-202
38. Turvey CL, Conwell Y, Jones MP, et al. Risk factors for late-life suicide: a prospective community-based study. Am J Geriatr Psychiatry 2002;10:398-406
39. Bruce ML, Ten Have TR, Reynolds CF, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: wwwa randomized controlled trial. JAMA 2004;291:1081-1091
40. Loebel JP. Completed suicide in late life. Psychiatr Serv 2005;56:260-262
41. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75